The CRISPR patent portfolio licensed via ERS (known as the CVC portfolio) is the most
comprehensive collection of proprietary rights to the fundamental CRISPR/Cas9 gene editing platform. Built on the Nobel Prize winning work of Emmanuelle Charpentier and Jennifer Doudna, ERS grants non-exclusive licenses to a growing list of issued and pending patent applications globally, in all fields excluding direct use as a human therapeutic.
ERS’s collaborative licensing approach promotes widespread adoption of CRISPR/Cas9 technology.
Non-exclusive licenses are available to companies involved in development and commercialization of CRISPR/Cas9 technology, products, and services.